FindTrial
Sign In

Autologous CD19/CD22 Chimeric Antigen Receptor T-cells

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Hebei Senlang Biotechnology Inc., Ltd.

Conditions

CD19 PositiveCD19+ and CD 22+ B-ALLCD22 PositiveMinimal Residual DiseaseProgressive DiseaseRecurrent B Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma

Early Phase 1

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
NCT05225831
Hebei Senlang Biotechnology Inc., Ltd.CD19+ and CD 22+ B-ALL
Start: 2021-08-15End: 2023-11-30Target: 100Updated: 2022-02-07

Phase 1

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
WithdrawnNCT04029038
M.D. Anderson Cancer CenterCD19 Positive, CD22 Positive, Minimal Residual Disease +7
Start: 2019-05-15End: 2022-11-16Updated: 2023-08-21